

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Ray G. Goodwin, Craig A. Smith, and
Mark R. Alderson

Attorney Docket No. : 2801-C

Serial No.: --to be assigned--

Filed: August 5, 1997

For: CYTOKINE DESIGNATED 41BB LIGAND

Prior Application: Filed: May 6, 1994

Serial No.: 08/236,918

Examiner: L. Spector

Group Unit: 1812

PRELIMINARY AMENDMENT

BOX SEQUENCE

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Prior to calculating the extra claim fee, please amend the referenced patent application as follows:

In the Specification:

On page 1, at line 8 after "This application" please insert is a divisional of currently pending U.S. Application Serial No.08/236,918, filed May 6, 1994, which--.

In the claims:

✓ Please cancel claims 1-25 and 28.

26. (amended) An antibody that is immunoreactive with a 4-1BB-L polypeptide [of claim 20] wherein the polypeptide is encoded by a DNA selected from the group consisting of:

(a) DNA comprising a nucleotide sequence selected from the group consisting of nucleotides 53-979 of the murine 4-1BB-L sequence of SEQ ID NO:1 and nucleotide 4-765 of the human 4-1BB-L sequence of SEQ ID NO:3;

BR
(b) DNA capable of hybridizing to a DNA of (a) under moderately stringent conditions and which encodes a 4-1BB-L capable of binding to a 4-1BB; and
(c) DNA which, due to the degeneracy of the genetic code, encodes a 4-1BB-L polypeptide encoded by a DNA of (a).

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

Respectfully submitted,

Janis C. Henry
Janis C. Henry
Registration no. 34,347

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE, Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: Aug. 5, 1997 Signed: James M. Keston